TP53 mutation	Chronic Myelomonocytic Leukemia	TP53 mutation	Chronic Myelomonocytic Leukemia	decitabine/cedazuridine Resistant: B - Late Trials ASH 2022 - 3 weeks (New B) decitabine / cedazuridine Resistant : B ASH 2022 - 3wk	decitabine/cedazuridine Resistant: B - Late Trials ASH 2022 - 3 weeks decitabine / cedazuridine Resistant : B ASH 2022 - 3 weeks - (New B)
RUNX1 mutation	Chronic Myeloid Leukemia	RUNX1 mutation	Chronic Myeloid Leukemia	Tyrosine kinase inhibitor Resistant: C3 – Early Trials ASH 2022 - 3 weeks (New C3) Tyrosine kinase inhibitor Resistant : C3 ASH 2022 - 3wk	Tyrosine kinase inhibitor Resistant: C3 – Early Trials ASH 2022 - 3 weeks Tyrosine kinase inhibitor Resistant : C3 ASH 2022 - 3 weeks - (New C3)
PHF6 mutation	Chronic Myeloid Leukemia	PHF6 mutation	Chronic Myeloid Leukemia	Tyrosine kinase inhibitor Resistant: C3 – Early Trials ASH 2022 - 3 weeks (New C3) Tyrosine kinase inhibitor Resistant : C3 ASH 2022 - 3wk	Tyrosine kinase inhibitor Resistant: C3 – Early Trials ASH 2022 - 3 weeks Tyrosine kinase inhibitor Resistant : C3 ASH 2022 - 3 weeks - (New C3)
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	venetoclax + ponatinib Sensitive: C3 – Early Trials ASH 2022 - 3 weeks (New C3) venetoclax + ponatinib Sensitive : C3 ASH 2022 - 3wk	venetoclax + ponatinib Sensitive: C3 – Early Trials ASH 2022 - 3 weeks venetoclax + ponatinib Sensitive : C3 ASH 2022 - 3 weeks - (New C3)
SETBP1 mutation	Chronic Myeloid Leukemia	SETBP1 mutation	Chronic Myeloid Leukemia	Tyrosine kinase inhibitor Resistant: C3 – Early Trials ASH 2022 - 3 weeks (New C3) Tyrosine kinase inhibitor Resistant : C3 ASH 2022 - 3wk	Tyrosine kinase inhibitor Resistant: C3 – Early Trials ASH 2022 - 3 weeks Tyrosine kinase inhibitor Resistant : C3 ASH 2022 - 3 weeks - (New C3)
IKZF1 mutation	Chronic Myeloid Leukemia	IKZF1 mutation	Chronic Myeloid Leukemia	Tyrosine kinase inhibitor Resistant: C3 – Early Trials ASH 2022 - 3 weeks (New C3) Tyrosine kinase inhibitor Resistant : C3 ASH 2022 - 3wk	Tyrosine kinase inhibitor Resistant: C3 – Early Trials ASH 2022 - 3 weeks Tyrosine kinase inhibitor Resistant : C3 ASH 2022 - 3 weeks - (New C3)
ASXL1 G646Wfs*12	Chronic Myeloid Leukemia	ASXL1 G646Wfs*12	Chronic Myeloid Leukemia	Tyrosine kinase inhibitor Resistant: C3 – Early Trials ASH 2022 - 3 weeks (New C3) Tyrosine kinase inhibitor Resistant : C3 ASH 2022 - 3wk	Tyrosine kinase inhibitor Resistant: C3 – Early Trials ASH 2022 - 3 weeks Tyrosine kinase inhibitor Resistant : C3 ASH 2022 - 3 weeks - (New C3)
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials ASH 2022 - 3 weeks (New C3) Tyrosine kinase inhibitor Sensitive : C3 ASH 2022 - 3wk	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials ASH 2022 - 3 weeks Tyrosine kinase inhibitor Sensitive : C3 ASH 2022 - 3 weeks - (New C3)
ASXL1 mutation	Chronic Myeloid Leukemia	ASXL1 mutation	Chronic Myeloid Leukemia	nilotinib Resistant: C3 – Early Trials ASH 2022 - 3 weeks (New C3) nilotinib Resistant : C3 ASH 2022 - 3wk	nilotinib Resistant: C3 – Early Trials ASH 2022 - 3 weeks nilotinib Resistant : C3 ASH 2022 - 3 weeks - (New C3)
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	olverembatinib Sensitive: C3 – Early Trials ASH 2022 - 3 weeks (New C3) olverembatinib Sensitive : C3 ASH 2022 - 3wk	olverembatinib Sensitive: C3 – Early Trials ASH 2022 - 3 weeks olverembatinib Sensitive : C3 ASH 2022 - 3 weeks - (New C3)
TET2 mutation	Chronic Myelomonocytic Leukemia	TET2 mutation	Chronic Myelomonocytic Leukemia	azacitidine Sensitive: C3 – Early Trials ASH 2022 - 3 weeks (New C3) azacitidine Sensitive : C3 ASH 2022 - 3wk	azacitidine Sensitive: C3 – Early Trials ASH 2022 - 3 weeks azacitidine Sensitive : C3 ASH 2022 - 3 weeks - (New C3)
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	SCO - 088 Sensitive: C3 – Early Trials ASH 2022 - 3 weeks (New C3) SCO - 088 Sensitive : C3 ASH 2022 - 3wk	SCO - 088 Sensitive: C3 – Early Trials ASH 2022 - 3 weeks SCO - 088 Sensitive : C3 ASH 2022 - 3 weeks - (New C3)
RXRA overexpression	Chronic Myeloid Leukemia	RXRA overexpression	Chronic Myeloid Leukemia	imatinib Sensitive: D – Preclinical ASH 2022 - 3 weeks (New D) imatinib Sensitive : D ASH 2022 - 3wk	imatinib Sensitive: D – Preclinical ASH 2022 - 3 weeks imatinib Sensitive : D ASH 2022 - 3 weeks - (New D)
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	asciminib Sensitive: A1 - Approval asciminib Sensitive : A1	asciminib Sensitive: A1 - Approval asciminib Sensitive : A1
No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	omacetaxine mepesuccinate Sensitive: A1 - Approval omacetaxine mepesuccinate Sensitive : A1	omacetaxine mepesuccinate Sensitive: A1 - Approval omacetaxine mepesuccinate Sensitive : A1
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
ABL1 T315I	Chronic Myeloid Leukemia	ABL1 T315I	Chronic Myeloid Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
Chr t(1;16)(q12;q11.2)	Chronic Myeloid Leukemia	Chr t(1;16)(q12;q11.2)	Chronic Myeloid Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	busulfan Sensitive: A1 - Approval busulfan Sensitive : A1	busulfan Sensitive: A1 - Approval busulfan Sensitive : A1
No biomarker	Chronic Myelomonocytic Leukemia	No biomarker	Chronic Myelomonocytic Leukemia	azacitidine Sensitive: A1 - Approval azacitidine Sensitive : A1	azacitidine Sensitive: A1 - Approval azacitidine Sensitive : A1
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	asciminib Sensitive: A1 - Approval asciminib Sensitive : A1	asciminib Sensitive: A1 - Approval asciminib Sensitive : A1
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	nilotinib Sensitive: A1 - Approval nilotinib Sensitive : A1	nilotinib Sensitive: A1 - Approval nilotinib Sensitive : A1
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	bosutinib Sensitive: A1 - Approval bosutinib Sensitive : A1	bosutinib Sensitive: A1 - Approval bosutinib Sensitive : A1
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
No biomarker	Chronic Myelomonocytic Leukemia	No biomarker	Chronic Myelomonocytic Leukemia	decitabine/cedazuridine Sensitive: A1 - Approval decitabine / cedazuridine Sensitive : A1	decitabine/cedazuridine Sensitive: A1 - Approval decitabine / cedazuridine Sensitive : A1
BCR-ABL1 V299L	Chronic Myeloid Leukemia	BCR-ABL1 V299L	Chronic Myeloid Leukemia	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	bosutinib Sensitive: A2 - Guideline bosutinib Sensitive : A2	bosutinib Sensitive: A2 - Guideline bosutinib Sensitive : A2
No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2
No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	YD312 Sensitive: A2 - Guideline YD312 Sensitive : A2	YD312 Sensitive: A2 - Guideline YD312 Sensitive : A2
BCR-ABL1 F317L	Chronic Myeloid Leukemia	BCR-ABL1 F317L	Chronic Myeloid Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2
BCR-ABL1 V299L	Chronic Myeloid Leukemia	BCR-ABL1 V299L	Chronic Myeloid Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 T315A	Chronic Myeloid Leukemia	BCR-ABL1 T315A	Chronic Myeloid Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 F317I	Chronic Myeloid Leukemia	BCR-ABL1 F317I	Chronic Myeloid Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 F317V	Chronic Myeloid Leukemia	BCR-ABL1 F317V	Chronic Myeloid Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 F317C	Chronic Myeloid Leukemia	BCR-ABL1 F317C	Chronic Myeloid Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 Y253H	Chronic Myeloid Leukemia	BCR-ABL1 Y253H	Chronic Myeloid Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
BCR-ABL1 E255K	Chronic Myeloid Leukemia	BCR-ABL1 E255K	Chronic Myeloid Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
BCR-ABL1 E255V	Chronic Myeloid Leukemia	BCR-ABL1 E255V	Chronic Myeloid Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2

Chronic Myeloid Leukemia

Associations(271)

Associations
(271)